Parenteral Treprostinil ( DrugBank: Treprostinil )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05203510 (ClinicalTrials.gov)	August 10, 2022	10/1/2022	A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension	A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction)	Pulmonary Arterial Hypertension	Drug: Parenteral Treprostinil;Drug: Oral Treprostinil	United Therapeutics	Lung Biotechnology PBC	Recruiting	18 Years	N/A	All	50	Phase 4	United States
2	NCT04062565 (ClinicalTrials.gov)	March 25, 2019	29/3/2019	Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH	A Prospective Trial to Evaluate Up-front Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Patients With Advanced Pulmonary Arterial Hypertension (IIR-3810)	Pulmonary Arterial Hypertension	Drug: Treprostinil Injectable Product;Drug: Riociguat Pill	University of Arizona	NULL	Recruiting	18 Years	N/A	All	20	Phase 3	United States